{
  "pmcid": "11884078",
  "sha256": "8d3078963c257bde436c20e760cab15e66cdd4f20b9e2e09275514c15ecb22a0",
  "timestamp_utc": "2025-11-09T23:22:06.896388+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.934017216642758,
    "reading_ease": 28.10588952654234,
    "word_count": 246
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "randomized controlled trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A multicenter, double-blind, randomized controlled trial was conducted"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included age over 18 and absence of pre-existing chronic kidney disease"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received biomarker-guided management, while the control group received standard care"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the effectiveness of novel biomarkers in the early diagnosis and prognosis of acute kidney injury"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of AKI within 48 hours"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Participants were randomized using a computer-generated sequence, with allocation concealment ensured by sealed envelopes"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for outcome assessors, patients, and clinicians"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomized, with 100 in each group, between January 2020 and June 2021"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group demonstrated a significant reduction in AKI incidence compared to the control group (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health"
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}